Yuliang Zhao - Concepedia

Author

Yuliang Zhao

Hebei Provincial Center for Disease Control and Prevention ORCID

Also Known As

Lin Du, Y L Zhao, Y Zhao, Yu-Liang Zhao, Yu-liang Zhao, Yuhong Zhao, Yuliang Zhao

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Hebei Provincial Center for Disease Control and Prevention Fudan University Sinovac Biotech National Institutes for Food and Drug Control Chinese Academy of Sciences

About

Yuliang Zhao is an author at Hebei Provincial Center for Disease Control and Prevention specializing in medicine, vaccination, and vaccine safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.2K
2	Epidemiology	5	5	373
3	Public Health	2	2	291
4	Biomedical Engineering	1	1	34
5	Cell Biology	1	1	52

Yuliang Zhao

Publications

Citations

H-Index

Page 1

	Year	Citations
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Zhiwei Wu, Yaling Hu, Miao Xu, The Lancet Infectious Diseases	2021	572
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial Bihua Han, Yufei Song, Changgui Li, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccinologyPhase 1/2Vaccine Development	2021	351
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials Gang Zeng, Qianhui Wu, Hongxing Pan, The Lancet Infectious Diseases VaccinationVaccine SafetyCoronary UnitThird DoseClinical Trials	2021	284
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial Xiaofeng Liang, Huaqing Wang, Junzhi Wang, The Lancet VaccinationVaccine SafetyCross-protectionInternational HealthPlacebo-controlled Trial	2009	254
Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case–control design Shan-Shan Zhen, Yue Li, Songmei Wang, Emerging Microbes & Infections VaccinationVaccine SafetyUniversal RotavirusVeterinary VaccineVaccine Development	2015	55
Down-regulation of PKCζ expression inhibits chemotaxis signal transduction in human lung cancer cells Ying Liu, Bing Wang, Jingna Wang, Lung Cancer Cancer ResearchSignal TransductionCell RegulationPkcζ Expression InhibitsMedicine	2008	52
Protective efficacy of PLGA microspheres loaded with divalent DNA vaccine encoding the ompA gene of Aeromonas veronii and the hly gene of Aeromonas hydrophila in mice Shanshan Gao, Na Zhao, Said Amer, Vaccine Plga MicrospheresMicrobial PathogensVirulence FactorGeneticsAeromonas Hydrophila	2013	46
A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Minjie Li, Juan Yang, Lin Wang, ImmunologyImmunodominanceVaccine HesitancyCovid-19Preventive Medicine	2021	37
Biosynthetic protein and nanocellulose composite fibers with extraordinary mechanical performance Lai Zhao, Lili Zhang, Xinquan Gu, Nano Today BiomanufacturingHigh-performance FiberNanocellulose Composite FibersBiomedical EngineeringNanocellulose	2022	34
Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination Yuliang Zhao, Bihua Han, Xinjiang Zhang, BMC Infectious Diseases	2019	32

Page 1